Ethinylestradiol/gestodene transdermal

Drug Profile

Ethinylestradiol/gestodene transdermal

Alternative Names: BAY86-5016; Estrogen/gestagen transdermal; Ethinylestradiol/gestodene transparent low dose contraceptive patch - Bayer HealthCare; FC Patch Fidencia; FC Patch Low; FC-patch; Fertility Control patch; Gestagen/estrogen transdermal; Gestodene/EE Patch; Gestodene/ethinylestradiol transdermal; Lisvy

Latest Information Update: 05 Oct 2016

Price : $50

At a glance

  • Originator Bayer Schering Pharma
  • Developer Bayer HealthCare Pharmaceuticals
  • Class Alkylated estrogenic steroids; Norpregnatrienes; Norpregnenes
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Contraception

Most Recent Events

  • 01 Aug 2016 Bayer completes a phase II trial for Contraception in Russia and Ukraine (NCT02550977)
  • 15 Mar 2016 Biomarkers information updated
  • 21 Sep 2015 Phase-III development is ongoing in Mexico
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top